Table 3.
Front-line chemotherapy regimens used, median number of cycles, serious adverse effects
| Protocol | Responders (N=17) | Non-Responders (N=35) | Cycles | Total (N=52) |
|---|---|---|---|---|
| CyVADic | 9 | 10 | Median=6 | 19 |
| CyADic | 3 | 9 | Median=5.5 | 12 |
| CyVDic | 5 | 5 | Median=9 | 10 |
| CyAV | 0 | 2 | Median=1.5 | 2 |
| CyA | 0 | 1 | 1 | 1 |
| CHOP | 0 | 1 | 2 | 1 |
| Imatinib | 0 | 1 | 1 | 1 |
| Cis + VP16 | 0 | 1 | 3 | 1 |
| AVDic | 0 | 1 | 6 | 1 |
| Cy + V + temozolomide | 0 | 1 | 12 | 1 |
| Carb + VP16 + ifosfamide | 0 | 1 | 4 | 1 |
| Tamoxifen | 0 | 1 | 4 | 1 |
| Temozolomide + bevacizumab + sorafenib | 0 | 1 | 4 | 1 |
Cy indicates cyclophosphamide; V, vincristine; A, doxorubicin; Dic, dacarbazine; Cis, cisplatin; VP-16, etoposide; Carb, carboplatin; CHOP, cyclophosphamide, doxorubicin, vincristine and prednisone
N= number of patients.